Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. (Q30891587)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Stefan W. Krause

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Andreas Hochhaus

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sebastien Rinaldetti

1 reference

ORCID Public Data File 2021

author name string

L Kalmanti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Saussele

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M C Müller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C T Dietz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Heinrich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

B Hanfstein

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

U Proetel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Fabarius

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Rinaldetti

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Dengler

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C Falge

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Oppliger-Leibundgut

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Burchert

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Neubauer

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Kanz

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Stegelmann

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Pfreundschuh

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

K Spiekermann

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C Scheid

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Pfirrmann

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Hasford

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Hehlmann

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

13 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1123-1132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Management of drug toxicities in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

The safety profile of imatinib in CML and GIST: long-term considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Harmonization of molecular monitoring of CML therapy in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Long-term imatinib therapy promotes bone formation in CML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Dysregulation of bone remodeling by imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.36

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25676422

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2015.36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676422%20AND%20SRC:MED&resulttype=core&format=json